AUTL

Autolus Therapeutics (AUTL)

Autolus Therapeutics PLC

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AUTL

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/18	05 : 39	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/05/17	21 : 27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/05/17	20 : 00	GlobeNewswire Inc.	Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/05/14	23 : 00	GlobeNewswire Inc.	Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/05/13	22 : 33	Edgar (US Regulatory)	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/05/13	20 : 23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/05/13	20 : 00	GlobeNewswire Inc.	Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/04/24	23 : 00	GlobeNewswire Inc.	Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/04/23	20 : 00	GlobeNewswire Inc.	Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/04/02	20 : 00	GlobeNewswire Inc.	Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/04/01	20 : 00	GlobeNewswire Inc.	Autolus Therapeutics Announces Changes to its Board of Directors	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/03/14	20 : 00	GlobeNewswire Inc.	Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/03/12	20 : 00	GlobeNewswire Inc.	Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/03/11	20 : 00	GlobeNewswire Inc.	Autolus Therapeutics announces publication in Blood Cancer Journal	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/29	21 : 00	GlobeNewswire Inc.	Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/24	07 : 28	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/22	21 : 00	GlobeNewswire Inc.	Autolus Therapeutics announces publication in Nature Communications	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/22	07 : 01	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/14	22 : 37	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/10	07 : 15	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/09	06 : 17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/08	21 : 00	GlobeNewswire Inc.	Autolus Announces Pricing of Underwritten Offering	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/08	20 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/08	19 : 45	GlobeNewswire Inc.	BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/08	12 : 00	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/02/01	06 : 10	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/01/27	03 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/01/23	21 : 00	GlobeNewswire Inc.	Autolus Therapeutics announces publication in ACS Chemical Biology	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/01/22	21 : 54	Dow Jones News	Autolus Therapeutics Gets BLA Acceptance for Obecabtagene Autoleucel	NASDAQ:AUTL	Autolus Therapeutics PLC
2024/01/22	21 : 00	GlobeNewswire Inc.	Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)	NASDAQ:AUTL	Autolus Therapeutics PLC